MC1R — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1309434	0.59	13/20
SCHEMBL1309435	0.59	13/20
SCHEMBL1308368	0.51	13/20
SCHEMBL1308372	0.51	13/20
SCHEMBL1309537	0.51	13/20
SCHEMBL1310521	0.51	13/20
SCHEMBL1309282	0.50	13/20
SCHEMBL1309284	0.50	13/20
SCHEMBL1308356	0.56	10/20
SCHEMBL1310559	0.54	10/20
SCHEMBL279121	0.50	10/20
SCHEMBL1324396	0.44	10/20
SCHEMBL1311438	1.00	9/20
Trifluoroacetic Acid (SCHEMBL1310554)	0.92	9/20
SCHEMBL1310555	0.80	9/20
SCHEMBL1309721	0.79	9/20
SCHEMBL1309971	0.79	9/20
SCHEMBL1310201	0.78	9/20
SCHEMBL1310839	0.78	9/20
SCHEMBL1325033	0.76	9/20

Clinical trials — most relevant to MC1R by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Undergraduate Skin Cancer Prevention Trial	PHASE3	RECRUITING
Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway	PHASE3	COMPLETED
Long Term Extension Trial of Setmelanotide	PHASE2/PHASE3	COMPLETED
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes	PHASE3	RECRUITING
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo	PHASE2	RECRUITING
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)	PHASE2	COMPLETED
Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis	PHASE2	COMPLETED
Carbidopa-levodopa in Neovascular AMD	PHASE2	COMPLETED
Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation	PHASE2	WITHDRAWN
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration	PHASE2	WITHDRAWN
Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)	PHASE2	COMPLETED
Effects of RM-493 on Energy Expenditure in Obese Individuals	PHASE1	COMPLETED
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)	PHASE1	COMPLETED
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study	EARLY_PHASE1	COMPLETED
Skin Health Online for Melanoma: Better Risk Assessment	nan	COMPLETED
Risk Information and Skin-cancer Education for Undergraduate Prevention	nan	COMPLETED
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy	nan	COMPLETED
Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma	nan	UNKNOWN
The Role of Melanocyte in Basal Cell Carcinoma	nan	UNKNOWN
Efficacy and Safety Trial of Using Ultra-Pulsed Shockwaves to Deliver Tranexamic Acid for the Treatment of Melasma	nan	UNKNOWN
The Efficacy in Treatment of Facial Melasma Combined With Thulium 1927-nm Fractional Laser and Topical H2R Antagonist	nan	COMPLETED
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
Melanocortin 4 Receptor Mutations and Obesity-associated Diseases	nan	COMPLETED
Using MC1R Genotype to Impact Melanoma Risk Behavior	nan	COMPLETED
Vanderbilt Childhood Obesity Registry	nan	COMPLETED
Efficacy and Tolerability of an Isobutylamido-thiazolyl-resorcinol Cream 0.2% for Facial Hyperpigmentation	nan	COMPLETED
Rare Obesity Cohorts With Food Behavioral Disorders : Better Diagnosis for Better Treatment	nan	RECRUITING
Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma	nan	RECRUITING
Study Evaluating the Efficacy of DOSE Formulations in Treating Melasma and Cutaneous Signs of Aging	nan	COMPLETED
Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MC1R binder may also engage these)

Protein	Name	Similarity
Q864K7	—	1.000	Q864K7 →
P56448	—	1.000	P56448 →
Q6A155	—	1.000	Q6A155 →
O19037	—	1.000	O19037 →
Q864I2	—	1.000	Q864I2 →
Q864K9	—	1.000	Q864K9 →
Q864J6	—	1.000	Q864J6 →
Q864K5	—	1.000	Q864K5 →
Q864L0	—	1.000	Q864L0 →
Q864K0	—	1.000	Q864K0 →
Q864F5	—	1.000	Q864F5 →
Q864J3	—	1.000	Q864J3 →
Q864K3	—	1.000	Q864K3 →
Q864K8	—	1.000	Q864K8 →
Q864G2	—	1.000	Q864G2 →
Q864K6	—	1.000	Q864K6 →
Q864F4	—	1.000	Q864F4 →
Q864I5	—	1.000	Q864I5 →
P56445	—	1.000	P56445 →
Q864K4	—	1.000	Q864K4 →
Q864G9	—	1.000	Q864G9 →
Q864G1	—	1.000	Q864G1 →
Q864J0	—	1.000	Q864J0 →
Q864J7	—	1.000	Q864J7 →
Q9TUK4	—	1.000	Q9TUK4 →
Q864J9	—	1.000	Q864J9 →
Q864K2	—	1.000	Q864K2 →
Q9TU05	—	1.000	Q9TU05 →
Q864J2	—	1.000	Q864J2 →
O77616	—	1.000	O77616 →